Forecast

The analysts' average price target is +41,93€ (+69,76%). The median is +36,06€ (+45,99%).

Buy	9
Hold	0
Sell	0

News Go to news feed

Takeover speculation lifts GH Research stock sharply in premarket

GH Research shares rose 16.4% premarket to $31.34 after reports that Eli Lilly is in advanced takeover talks with AtaiBeckley, sparking speculation of further M&A activity in the psychedelics sector. An RBC analyst viewed GH Research as the main beneficiary of the news and reiterated expectations of targeted interest from large pharma firms in the pipeline, fueling institutional buying. Recent positive signals from the FDA and a government regulation to accelerate the development of psychedelic therapies also provided support. » More on de.investing.com
GH Research PLC announces at-the-market stock offering of up to US$200 million

GH Research PLC has entered into an agreement with Stifel for an at-the-market offering pursuant to which the company may sell common shares from time to time with an aggregate value of up to US$200 million. The sales will be made pursuant to Rule 415(a)(4) of the Securities Act and are covered by a previously filed registration statement on Form F-3. A prospectus supplement and related documents have been filed with the SEC and are available as exhibits to Form 6-K. » More on de.investing.com
GH Research calls annual general meeting for June 25 in Dublin

GH Research has informed its shareholders of an annual general meeting to be held on June 25, 2026 at 13:30 Irish time at Joshua Dawson House in Dublin. The company is making the agenda, proxy materials and voting cards available for registered shareholders and brokers. At the same time, the directors’ report and the 2025 financial statements prepared under Irish law have been published; the information is provided based on a recent SEC filing. » More on de.investing.com

Financials

In the last quarter, GH RESEARCH PLC had revenue of 0.00€ and net profit of −13.27m€

(EUR)	Jun 2026	YoY
Revenue	0.00	-
Gross profit	0.00	-
Net profit	−13.27m	68,39%
EBITDA	−13.19m	68,97%

Fundamentals

Metric	Value
Market capitalization	+1.70b€
Number of shares	68.56m
52-week high/low	+26,99€ - +10,16€
Dividends	No
Beta	1,29
P/E ratio	−28,92
PEG ratio	+1,01
P/B ratio	+5,35
P/S ratio	0,00

Company profile

GH Research PLC, ein biopharmazeutisches Unternehmen im klinischen Stadium, beschäftigt sich mit der Entwicklung verschiedener Therapien zur Behandlung psychiatrischer und neurologischer Störungen. Das Unternehmen konzentriert sich auf die Entwicklung von 5-Methoxy-N,N-Dimethyltryptamin (5-MeO-DMT)-Therapien zur Behandlung von Patienten mit behandlungsresistenter Depression (TRD). Das führende Programm ist GH001, ein inhalierbarer 5-MeO-DMT-Produktkandidat, der zwei klinische Studien der Phase 1 und eine klinische Studie der Phase 1/2 bei Patienten mit TRD abgeschlossen hat. Das Unternehmen entwickelt auch GH002, einen injizierbaren 5-MeO-DMT-Produktkandidaten, und GH003, einen intranasalen 5-MeO-DMT-Produktkandidaten, die sich in präklinischen Entwicklungsstudien mit Schwerpunkt auf psychiatrischen und neurologischen Erkrankungen befinden. GH Research PLC wurde im Jahr 2018 gegründet und hat seinen Sitz in Dublin, Irland.